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Abstract 
 
Purpose  
To develop a consensus based set of core outcomes for studies in multimorbidity. 
Methods 
Consensus study following the COS-STAR guidelines for the design and reporting of core 
outcome sets.  An expert Delphi Panel completed a web-based survey with two Rounds.  
Panellists were presented with a range of outcomes that had been identified in previous 
workshops and a related systematic review. They indicated their level of agreement on 
inclusion of each outcome using a Likert scale and outcomes reaching a pre-specified 
consensus level were included. 
Results: 30 panellists were invited to participate and 26 agreed, from 13 countries. All 26 
completed both rounds of the survey. The Delphi Panel reached consensus on 17 core 
outcomes for multimorbidity. The highest ranked outcomes were health related quality of 
life, mental health outcomes and mortality. Other outcomes were grouped into overarching 
themes of patient reported impacts and behaviours (treatment burden, self-rated health, 
self-management behaviour, self-efficacy, adherence); Physical activity and function 
(activities of daily living, physical function, physical activity); consultation related 
(communication, shared decision making, prioritisation); and health systems (healthcare 
utilisation, costs, quality of healthcare).  
Conclusions: This consensus study involved a wide range of international experts who 
identified a large number of outcomes for multimorbidity intervention studies. The results 
suggest that quality of life, mortality and mental health outcomes should be regarded as 
essential core outcomes. However, researchers should also consider the full range of 
outcomes when designing studies to capture important domains in multimorbidity 
depending on individual study aims and interventions.  
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Introduction  
The COMET (Core Outcome Measures in Effectiveness Trials) is an initiative which aims to 
develop agreed standardised sets of outcomes, known as ‘core outcome sets’ (COS) 
(http://www.comet-initiative.org/).(1) COS represent the minimum that should be 
measured and reported in all clinical trials of a specific condition or conditions.(1) 
Multimorbidity is commonly defined as the co-existence of two or more chronic conditions 
in an individual.(2) Its impacts include reduced health-related quality of life, increased 
psychological distress, functional difficulties, increased healthcare utilisation and 
heightened mortality risk.(3-8) Current randomised controlled trials tend to adopt a single-
disease focus, resulting in a paucity of relevant evidence for the management of patients 
with multimorbidity.(9) There are a growing number of trials examining the effectiveness of 
interventions to address the specific experiences of patients with multimorbdity. ( Cochrane 
review ref).  The systematic review of these studies highlights challenges synthesising the 
evidence due to differences between studies including outcomes. The 2016 UK National 
Institute of Health and Care Excellence (NICE) Guidance on Multimorbidity stresses the need 
to design interventions and transform health services by addressing multimorbidity in both 
clinical guidelines and clinical practice.(10) This NICE Guidance and related systematic and 
clinical reviews(9-11), highlight the need for consensus regarding multimorbidity outcomes, 
so that evidence can be synthesised and is based on outcomes reflecting the priorities of all 
stakeholders , particularly patients.  
 
The aim of this study was to identify a COS for multimorbidity research studies using a 
Delphi consensus process with an international panel of experts. The scope of this COS 
included studies of all intervention types targeting adults with multimorbidity and does not 
address the issue of patients with multimorbidity participating in single condition studies as 
these interventions are conceptually different. Research studies including a named index 
condition (e.g. hypertension, diabetes) plus another condition (referred to as co-morbidity 
studies) were excluded, as the aim was to develop a COS reflecting the heterogeneous 
nature of multimorbidity.  
 
The specific objectives were: 
1. To identify outcomes  and outcome metrics that had previously been used in 
intervention studies for multimorbidity. 
2. To develop a consensus based set of core outcome for intervention studies in 
multimorbidity. 
3. To identify related outcome metrics potentially relevant for multimorbidity 
studies  
 
Methods 
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A protocol of this project was registered with the COMET initiative and is available at: 
http://www.comet-initiative.org/studies/details/822?result=true .(12) The Core Outcome 
Set-STAndards for Reporting (COS-STAR) Equator Network guidelines were used for the 
reporting of this core outcome set.(1) COS can be considered in terms of what to measure, 
which we refer to as outcomes and  how to measure them, which we refer to as metrics. 
(trialsjournal.biomedcentral.com/articles/10.1186/s13063-017-1978-4) 
 
The Steering Group 
A Steering Group oversaw the development of the COS and consisted of academic family 
practitioners and primary care researchers with a specific interest in multimorbidity; all 
members are authors on this paper.   
 
The development of a preliminary set of core outcomes for multimorbidity: Information 
sources  
The Steering Group developed a list of relevant outcome for multimorbidity intervention 
studies using a comprehensive strategy of workshop discussions and review of outcomes in 
existing peer reviewed publication. This list of potential outcomes was developed over 
several years at academic primary care meetings and workshops attended by the author 
group and other experts in multimorbidity research. (13) (see Appendix 1) Members of the 
steering group also reviewed  studies in the recently updated Cochrane review of the 
effectiveness of interventions for patients with multimorbidity and identified outcomes and 
related metrics reported in this review.(11) This approach was taken as the Cochrane 
systematic review involved a comprehensive systematic literature search across multiple 
databases and had been conducted relatively recently. These outcome and related metrics 
were compiled into an online survey using Survey Monkey© (Appendix 2).(14) 
 
Consensus process 
The Delphi technique is a commonly used consensus technique.(15) The Steering Group 
identified a panel of international experts with broad stakeholder representation. 
Participants were selected based on their interest in multimorbidity research or through 
their existing membership of patient panels supporting multimorbidity research in Ireland, 
the UK and Canada.  The final panel included a multidisciplinary range of experts and 
stakeholders (see Appendix 3). 
 
The survey containing the preliminary COS was first piloted (to test usability) by members of 
academic staff in the departments of the steering group and modified accordingly. 
Following formation of the Delphi panel, all potential members received the first round 
questionnaire via an on-line survey, SurveyMonkey©.(14) A full copy of this questionnaire 
including the instructions given to participants is included as Appendix 2. 
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Panel members were asked to rate the importance of each potential outcome and were also 
presented with a range of potential metrics. They were also given an opportunity to suggest 
additional outcomes or metrics if desired. A web link to the outcome metrics presented was 
also included to support the panel’s decision making. (See Appendix 2).  
 
Sample size 
Based on previous studies showing the range in sizes of Delphi panels, we anticipated that a 
purposively selected sample of at least 15 experts would adequately cover issues in the 
proposed outcome set.(16) Only those responding to the first round were included in the 
second round. Based on previous Delphi studies a total of 30 panellists were invited, 
assuming an approximate response rate of 50%.  
 
Round 1 analysis 
Panellists were asked to indicate their level of agreement for the inclusion of each outcome 
domain using a 5-point Likert scale (1=strongly disagree, 2=disagree, 3=ambivalent, 4=agree, 
5= strongly agree). For each statement, the median response and interquartile range (IQR) 
were calculated. Where the lower limit of the IQR was >3, the outcome domain was 
accepted as included in the core set. In statements where the upper limit of the IQR was <3, 
the outcome measure was rejected. If the IQR of a statement included 3, the language used 
in the statement was revised following recommendations from the panel and included in 
the second round. All members of the Steering Group were involved in reviewing 
statements and in refining the core outcomes included.  
 
Round 2 
The Delphi process underwent two rounds. Outcome remaining from the first Round were 
presented with the same definition of consensus as used for Round 1. Participants were not 
informed of the previous round scores but would have been aware that the remaining 
outcomes had not achieved consensus in Round 1. The wide range of potential outcome 
metrics included in Round 1 indicated that it was beyond the scope of the current study to 
reach agreement on metrics so these were not presented to the panellists for consideration 
for Round 2. All statistical analyses were performed using STATA version 13.0 (StataCorp LP, 
College Station, TX, USA). 
 
Ethical considerations 
Ethical approval for this study was granted by the Human Research Ethics committee at the 
Royal College of Surgeons in Ireland (RCSI) medical school. All participants were contacted 
by email with detailed information regarding the study. Patient and public representatives 
were contacted initially with a separate email invitation that included a specific public/ 
patient participant information leaflet. For all panel members, once a signed consent form 
was received the panel member was sent another email with a link to the 
SurveyMonkey©questionnaire.  
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Results  
An overview of the COS development process is provided in Figure 1. Of the 30 potential 
Delphi panel participants, 26 responded (87% response rate). Five panellists were patient or 
public representatives. Two people formally declined and two did not respond to several 
emails. (See Appendix 3). 
Results: Round 1 Delphi Panel 
Of the 30 preliminary outcomes presented to the panel, 11 had a median and IQR score >3 
and were therefore included in the COS after round 1. (See Table 1) No outcomes were 
excluded following Round 1 and no additional outcomes were identified. A list of potential 
metrics was identified during Round 1 and is presented in Appendix 4.  
 
Results: Round 2 
The remaining 19 outcomes (IQR included 3) were presented to all 26 panel members for 
Round 2 of the Delphi process and all completed Round 2. A further six outcomes had 
median and IQR scores > 3 so were included, giving a total of 17 final outcomes in the COS. 
The steering group divided these 17 core outcomes into linked groups in an effort to clarify 
the key areas for consideration when choosing outcomes for individual studies from the 
COS. (See Table 2) 
 
 
Discussion   
Summary 
A Delphi Consenus panel with 26 experts from 13 countries agreed on 17 core outcomes for 
multimorbidity intervention studies (COSmm).  The highest ranked outcomes were health 
related quality of life (HRQol), mental health outcomes and mortality. Given the number of 
outcomes we have grouped the remaining included outcomes into overarching themes of 
patient reported activities and behaviours, physical activity and function, consultation 
related outcomes and outcomes of importance to health systems including costs.  
 
While the COSmm represents a large number of outcomes for consideration, this reflects 
the broad nature of multimorbidity and is consistent with the range of outcomes in studies 
included in the Cochrane systematic review on multimorbdity interventions.(11) Given the 
likely variation in intervention types for people with multimorbidity, individual studies will 
use outcomes that reflect their aims and underlying mechanisms.(13) Our results suggest 
that all studies should consider HRQoL, mental health outcomes and mortality as kay 
outcomes and consider other outcomes within the COSmm based on ehri own individual 
study. While few individual studies will be designed or powered to detect changes in 
mortality, our panellists regarded it as an important outcome and inclusion of mortality in 
studies would facilitate its inclusion in meta-analyses in future systematic reviews. We 
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would also caution that if all outcomes in the COSmm were used in an individual study, it 
would likely lead to excessive burden on study participants and could lead to higher risk of 
Type 1 errors in interpreting results. We also acknowledge that many of the outcomes that 
were excluded could also be considered important, but the level of agreement amongst 
panellists was not sufficiently strong to include them and some may still be relevant in 
multimorbidity trials depending on the interventions involved. 
 
One of the objectives of this study was to consider metrics which have been used previously 
for each of the core outcomes. The responses in Round 1 suggested that a consensus 
process for the use of these metrics woud be very complex and challenging. However, the 
metrics identified during the process will likely be of interest to researchers and other 
stakeholders and have been included as an appendix. Methodology on the development of 
core outcome sets is evolving (17, 18), and we acknowledge that this COS will need to be 
updated regularly as new outcomes and metrics are developed over time.  
 
Comparison with other COS 
This COS was developed spcifically for studies of interventions for patients with 
multimorbidity but other studies have used consensus approaches to develop outcomes to 
measure the quality of care for people with multimorbdity using the electronic healthcare 
record (Bayliss et al. JAGS 2016). A range of different consensus process methods have been 
used in the development of COSs.(1) We chose to use a Delphi Panel approach based on our 
previous experience and a review of COS literature.(16, 18, 19)  Other potential approaches 
include expert panel groups, nominal group techniques, semi-structured group discussions 
and questionnaires.(18) Face-to-face approaches allow greater discussion but are restricted 
by limited accessibility for international stakeholders. Some elements of other approaches 
were employed through the use of workshops to identify the draft COS prior to the 
consensus process. This is an evolving area of research and there is no clear evidence 
suggesting benefit of one consensus approach over another.(16) We chose an online Delphi 
method as it allowed for involvement of clinicians, researchers and patients in multiple sites 
across continents. The method also allowed for purposive selection of a panel to ensure 
representation of a range of stakeholders from different countries and healthcare systems 
with both professional and patient representation.(20)   
 
A high level of consensus was achieved after the first round for 11 outcomes. This is higher 
than might have been expected. There are clearly many important outcomes for evaluating 
care delivered to complex populations. After the first round we consulted the COMET group 
regarding the number of outcomes and they provided helpful feedback, which suggested 
that our COS is not unusual given the broad scope of multimorbidity. 
We used a five-point Likert scale for outcome scoring. Other COSs have been developed 
using alternative outcome scoring methods, which may have been more appropriate.(1) 
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These alternatives include a higher number of options on the Likert scale or scoring based 
on average agreement scores. The methodology in core outcome sets has been developing 
rapidly over the last few years and there is no clear evidence as yet on which is the best 
scoring method. The COS Star Guidance was produced after we had published our protocol 
and secured ethical approval.(1) The potential to change our approach to outcome scoring 
was considered after Round 1 but we decided not to deviate from our protocol at that 
point.  
 
Strengths and weaknesses 
This multimorbidity COS was developed over a period of several years by an international 
group of researchers working in this area. It built on a number of workshops held with a 
wide range of participants at different international primary care meetings. We identified a 
Delphi Panel consisting of a broad range of experts with experience in multimorbidity 
research from 13 countries and with public and patient representation. Identifying 
appropriate public and patient representation was a challenge given the broad nature of 
multimorbidity, but we worked with experienced research groups to identify appropriate 
patient representatives from three different countries. A further strength  was the very high 
response rate for the first round of the consensus process and 100% participation for the 
second round.  
 
One potential limitation of this COS is the high number of outcomes identified by the panel. 
There was already a high number of included outcomes after Round 1 and we provided a 
cover letter for the Round 2 survey that stressed to panellists that there was not necessarily 
a need to identify further outcomes. Despite this, a further six outcomes were added. With 
hindsight, a greater number of Likert scale options might have allowed for more 
discrimination between outcomes and facilitated ranking of outcomes, though we had not 
intended to rank outcomes when designing the study. Another limitation may relate to our 
decision not to provide panellists with feedback on scores from other panel members for 
Round 2. We did this to ensure that panellists could make independent judgements and 
avoid moving towards a group average score.(20) Guidance on the use of Delphi techniques 
recommend that a measure of distribution around final scores should be reported, which 
we have done.  Reporting of the final scores alone  can mask major disagreement within the 
group, which might be the case if there was a wide distribution around scores(19) Our 
results do not suggest that this was the case.  
 
Panel size and selection is always a key consideration and potential limitation for any Delphi 
process. We chose to identify a purposive sample of participants with some prior exposure 
to the concept of multimorbidity given the complexity of this topic. This could be seen as a 
limitation in that it did not open up the COS to a wider group. However, the broad nature of 
multimorbidity and the frequent debate about its definition and construct (add refs here) 
were repeated themes at all the workshops that led to the development of the preliminary 
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COS and these workshops were open to all attendees at the two largest primary care 
research meetings in North America and Europe. We therefore, felt it was appropriate to 
limit the Delphi panellists to those with prior exposure to multimorbidity as they had 
already considered issues as to whether multimorbidity itself represents a construct or not.  
 
Other COS studies have used larger panel sizes to increase representation. However, there 
tends to be a lower response rate for larger panels.(21) Some studies use snowballing 
techinques allowing open access to an online survey, which will lead to larger numbers of 
participants. However, this does not necessarily ensure broad and balanced representation 
of key stakeholders. Another potential limitation for our study is that while we included 
panellists from 13 countries, they were all based in high income countries.. In addition, 
while we included patient representatives as Delphi panel members, like many previous COS 
studies, it is a limitation that they were not directly involved in the development of the intial 
COS.(20)   
 
Conclusion 
This consensus study involved a wide range of international experts who identified a large 
number of core outcomes for multimorbidity intervention studies. Such studies are likely to 
vary depending on target populations and intervention types so given the scope of 
multimorbidity the large number of outcomes identified is not surprising. The results 
suggest that quality of life, mortality and mental health outcomes should be regarded as 
essential core outcomes.  However, researchers should also consider the full range of 
outcomes in this COS for multimorbidity depending on their individual study aims and 
interventions.  
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Figure 1: Overview of multimorbidity COS development process 
 
 
  
Identification of 30 potential core 
outcomes as well as relevant metrics by the 
steering group 
 
Delphi: Round 2 (n=26 panel members)  
6 outcomes scored median and IQR >3 and 
were included in the COS. 
                 
 
Delphi Round 1 
No new outcomes identified from 
respondents. 
19 outcomes taken forward to Round 2 
(IQR included score of 3). 
Metrics removed for Round 
2 and rewording of one 
Likert scale answer option, 
following feedback from 
one participant 
Final agreed multimorbidity COS 
Scored by 26 panel members in 
Round 1 and 2 
Final set: 17 core outcomes  
Final 17 outcomes included in COS 
1. Health related quality of life 
2. Mental health 
3. Mortality 
4. Treatment burden 
5. Self-rated health 
6. Self-management behaviour 
7. Self-efficacy 
8. Adherence  
9. Activities of daily living 
10. Physical function 
11. Physical activity 
12. Communication 
13. Shared decision making 
14. Prioritisation 
15. Healthcare utilisation 
16. Costs 
17. Patient rated quality of healthcare 
Delphi: Round 1 (n=26 panel members) 
11 outcomes scored median and IQR >3 and 
were included in the final COS 
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Table 1:  Results Round 1 and Round 2 Delphi process 
Domain  Number 
Responses 
Median and IQR 
Round 1 
 
First Round: Outcomes  included  
Health Related Quality of 
Life (HRQoL) 
25 
 
5 (4-5)  
Mental Health 25 5 (4-5)  
Mortality 26 4.5 (4-5)  
Acitivities of Daily Living 
(ADL) 
25 4 (4-5)  
Physical Function 23 4 (4-5)  
Self Rated Health 25 4 (4-5)  
Treatment Burden 25 4 (4-5)  
Communication 25 4 (4-5)  
Healthcare utilisation  24 4 (4-5)  
Costs 24 4 (4-5)  
Adherence 24 4 (4-4)  
Domains to exclude: None 
Second round: Outcomes included 
 N  
Round 1 
N 
Round 2 
Median and IQR 
Round 1 
Median and IQR 
Round 2 
Shared decision making 25 26 4 (3-5) 4 (4-5) 
Quality healthcare 24 26 4 (3-5) 4 (4-5) 
Prioritisation 24 26 4 (3-4.5) 4 (4-5) 
Self-management 
Behaviour 
25 26 4 (3-4) 4 (4-4) 
Self-Efficacy 25 26 4 (3-4) 4 (4-4) 
Physical Activity  24 26 4 (3-4) 4 (4-5) 
Second round: Outcomes excluded (no agreement) 
Generic Symptom 
Measures 
25 26 4 (3-4) 4 (3-4) 
Social Role 25 26 4 (3-4) 4 (3-4) 
Social Support 25 26 4 (3-4) 4 (3-4) 
Patient Enablement 25 26 4 (3-5) 4 (3-4) 
System factors 
(continuity) 
23 26 4 (3-4) 4 (3-4) 
Treatment Satisfaction 24 26 4 (3-4) 4 (3-4) 
Social Inclusion 25 26 4 (2-4) 4 (3-4) 
Smoking 21 26 3.5 (2-4) 3 (3-4) 
Alcohol 22 26 3.5 (2-4) 3 (3-4) 
Nutrition 24 26 3.5 (2-4) 3 (3-4) 
Obesity 26 26 3 (2-4) 3 (2-4) 
Illness perceptions 23 26 3 (2-4) 3 (3-4) 
Self-Esteem 25 26 3 (2-4) 3 (3-4) 
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Table 2. COS for multimorbidity 
Domains (n=17) 
Highest scoring outcomes  
HRQoL  
Mental Health 
Mortality 
Patient reported impacts and behaviours 
Treatment Burden 
Self-Rated Health 
Self-management Behaviour 
Self-Efficacy 
Adherence 
Physical activity and function 
Activities of Daily Living 
Physical Function 
Physical Activity 
Consultation related 
Communication  
Shared decision making 
Prioritisation 
Health systems  
Healthcare utilisation 
Costs 
Quality healthcare (patient rated) 
 
